作为潜在的抗阿尔茨海默氏症药物的新型提亚-提亚醇:通过in silico研究的合成和分子相互作用
Shoaib Khan1, Tayyiaba Iqbal1, Rafaqat Hussain2
1Department of Chemistry, Abbottabad University of Science and Technology, Abbottabad, Pakistan.
Future medicinal chemistry
|July 3, 2025
概括
新的希夫基衍生物显示出强大的抗阿尔茨海默症和抗氧化作用. 化合物8是一种三甲基替代衍生物,在抑制关键酶方面表现优于标准药物多尼佩西尔,突出显示了它在神经退行性疾病治疗中的潜力.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病是一种进展性神经退行性疾病,其特点是认知能力下降.
- 乙胆酶 (AChE) 和丁胆酶 (BuChE) 抑制剂是阿尔茨海默病的关键治疗策略.
- 氧化应激在神经退行性疾病的发病过程中起着重要作用.
研究的目的:
- 为了合成和评估新型的亚醇基希夫基衍生物,用于抗阿尔茨海默氏症和抗氧化作用.
- 确定有希望的类似药物的候选人用于治疗神经退行性疾病.
- 研究这些化合物的结构-活性关系.
主要方法:
- 16个希夫基衍生物的合成.
- 在体外测定ACHE和BuChE抑制.
- 对抗氧化活性进行DPPH激素清除试验.
- 分子对接研究. 分子对接研究.
- 用于药理动力学和毒性评估的ADMET分析.
主要成果:
- 含有三甲基的第8种化合物,与多尼佩西尔相比,对AChE和BuChE表现出优异的抑制活性.
- 衍生品3,7和12也显示出显著的抗阿尔茨海默症和抗氧化活性.
- 分子对接证实了与酶活性部位的有利结合相互作用.
- 对ADMET的分析表明,活性化合物具有良好的药物相似性和安全性.
结论:
- 合成的希夫基衍生物,特别是化合物8,具有显著的抗阿尔茨海默氏症和抗氧化能力.
- 这些化合物代表了开发神经退行性疾病新型多功能疗法的有希望的领先候选人.
- 需要进一步的研究,以在临床前模型中探索它们的治疗疗效.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.1K
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K